Countries Australia
ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. St...
September 29, 2023 | News
An innovative technology that captures high-quality images of a tumor in six seconds is being used to guide cancer treatments for patients receiving care a...
September 29, 2023 | News
Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design...
September 27, 2023 | News
The University of Adelaide's Experts Lead Landmark Australian Study on Back and Neck Pain A team of experts from the University of Adelaide is spearheadin...
September 18, 2023 | News
Societies around the world are being confronted by inexorable evidence of falling fertility rates and environmental collapse that pose major threats to hum...
September 08, 2023 | News
In this exclusive interview with Dr. Jerome Boyd-Kirkup, Chief Scientific Officer of Hummingbird Bioscience, BioPharma APAC delve into the recently i...
September 06, 2023 | News
Introduction Nestled on the vast, sunburned continent known for its stunning landscapes and unique wildlife, the Australian BioPharma industry has...
September 05, 2023 | Analysis
ST to partner with Dutch biotech company Treeway BV First CNS therapy in ST therapeutic portfolio The therapy is known as TW001 and is a un...
August 28, 2023 | News
The first patient, a 29-year-old woman from Australia who has suffered from debilitating headaches since the age of 14, experienced immediate and...
August 24, 2023 | News
IMG-007 is a humanized IgG1 monoclonal antibody (mAb) that specifically binds to the OX40 receptor. Its Fc region has been bioengineered, resulting in...
August 16, 2023 | News
The Phase III Illuccix China study (ClinicalTrials.gov ID: NCT05847348) is a prospective, open-label, single-arm, multicenter study in Chinese...
August 11, 2023 | News
Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) ha...
August 11, 2023 | News
IPAX-2 (ClinicalTrials.gov Identifier: NCT05450744) is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with externa...
August 08, 2023 | News
The incubator will be the first health-focused incubator funded by the NSW government to support pre-revenue health-tech startups in bridging the gap betwe...
August 04, 2023 | News
Most Read
Bio Jobs
News